Andere Sprachen InspireMD, Inc.

Aktien

A3CMP3

US45779A8466

NSPR

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 13.05.2024			% 5 Tage	% 1. Jan.
2.4 ^USD	+7.38%		+13.20%	-14.59%

06.03.	Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024
05.03.	InspireMD, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th	07.05.
InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference	03.04.
InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024	26.03.
Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M	06.03.
InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	06.03.
InspireMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th	28.02.
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System	12.02.
InspireMD Gets CE Mark Recertification From the European Union	31.01.
InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework	31.01.
InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America	03.01.
InspireMD, Inc. Announces Appointment of Pete Ligotti as Executive Vice President and General Manager of North America	03.01.
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System	20.12.
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions	27.11.
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions	27.11.
Earnings Flash (NSPR) INSPIREMD Reports Q3 Revenue $1.6M	06.11.
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update	06.11.
InspireMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	06.11.
InspireMD to Participate in Upcoming November Investor Conferences	02.11.
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23	01.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen InspireMD, Inc.

Aktien

A3CMP3

US45779A8466

NSPR

Andere Sprachen

Filter